Sorafenib — CAS 284461-73-0

Sorafenib is an oral multikinase inhibitor that targets multiple receptor tyrosine kinases (VEGFR, PDGFR) and Raf kinases. It is used in the treatment of hepatocellular carcinoma, renal cell carcinoma, and differentiated thyroid cancer. Mediocon Inc manufactures GMP-compliant Sorafenib API at its Aurangabad facility to international pharmacopoeial standards.

• Hepatocellular carcinoma (HCC)
• Renal cell carcinoma (RCC)
• Differentiated thyroid carcinoma
• Multi-kinase targeted cancer therapy

• GMP Certified manufacturing facility in Aurangabad, Maharashtra, India
• Full pharmacopoeial compliance: IP / BP / EP / USP standards
• Complete documentation: Certificate of Analysis (CoA), MSDS, Certificate of Origin
• Stringent in-process quality control at every manufacturing stage
• HPLC purity testing and spectroscopic identification (IR, NMR)
• Cold-chain and controlled-environment storage facilities available
• Exported to 40+ countries with full regulatory support